128 related articles for article (PubMed ID: 35970679)
1. Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration.
Inker LA; Grams ME; Guðmundsdóttir H; McEwan P; Friedman R; Thompson A; Weiner DE; Willis K; Heerspink HJL;
Am J Kidney Dis; 2022 Oct; 80(4):513-526. PubMed ID: 35970679
[TBL] [Abstract][Full Text] [Related]
2. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
[TBL] [Abstract][Full Text] [Related]
3. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Levey AS; Inker LA; Matsushita K; Greene T; Willis K; Lewis E; de Zeeuw D; Cheung AK; Coresh J
Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Levey AS; Cattran D; Friedman A; Miller WG; Sedor J; Tuttle K; Kasiske B; Hostetter T
Am J Kidney Dis; 2009 Aug; 54(2):205-26. PubMed ID: 19577347
[TBL] [Abstract][Full Text] [Related]
5. Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases.
Damron KC; Friedman R; Inker LA; Thompson A; Grams ME; Guðmundsdóttir H; Willis K; Manley T; Heerspink HL; Weiner DE
Kidney Med; 2022 Apr; 4(4):100442. PubMed ID: 35372821
[TBL] [Abstract][Full Text] [Related]
6. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
Badve SV; Palmer SC; Hawley CM; Pascoe EM; Strippoli GF; Johnson DW
Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
[TBL] [Abstract][Full Text] [Related]
7. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
Inker LA; Heerspink HJL; Tighiouart H; Levey AS; Coresh J; Gansevoort RT; Simon AL; Ying J; Beck GJ; Wanner C; Floege J; Li PK; Perkovic V; Vonesh EF; Greene T
J Am Soc Nephrol; 2019 Sep; 30(9):1735-1745. PubMed ID: 31292197
[TBL] [Abstract][Full Text] [Related]
8. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
[TBL] [Abstract][Full Text] [Related]
11. Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators.
Holtkamp F; Gudmundsdottir H; Maciulaitis R; Benda N; Thomson A; Vetter T
Am J Kidney Dis; 2020 Jan; 75(1):6-8. PubMed ID: 31672251
[No Abstract] [Full Text] [Related]
12. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study.
Hasegawa T; Sakamaki K; Koiwa F; Akizawa T; Hishida A;
Clin Exp Nephrol; 2019 Feb; 23(2):189-198. PubMed ID: 30069609
[TBL] [Abstract][Full Text] [Related]
13. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Eckardt KU; Bansal N; Coresh J; Evans M; Grams ME; Herzog CA; James MT; Heerspink HJL; Pollock CA; Stevens PE; Tamura MK; Tonelli MA; Wheeler DC; Winkelmayer WC; Cheung M; Hemmelgarn BR;
Kidney Int; 2018 Jun; 93(6):1281-1292. PubMed ID: 29656903
[TBL] [Abstract][Full Text] [Related]
14. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society.
Friedman AN; Schauer PR; Beddhu S; Kramer H; le Roux CW; Purnell JQ; Sunwold D; Tuttle KR; Jastreboff AM; Kaplan LM
Am J Kidney Dis; 2022 Dec; 80(6):783-793. PubMed ID: 36280397
[TBL] [Abstract][Full Text] [Related]
15. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society.
Friedman AN; Schauer PR; Beddhu S; Kramer H; le Roux CW; Purnell JQ; Sunwold D; Tuttle KR; Jastreboff AM; Kaplan LM
Obesity (Silver Spring); 2022 Dec; 30(12):2340-2350. PubMed ID: 36268562
[TBL] [Abstract][Full Text] [Related]
16. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
17. Improving Clinical Care for Children With CKD: A Report From a National Kidney Foundation Scientific Workshop.
Warady BA; Feldman DL; Bell LE; Bacchetta J; Denburg MR; Flynn JT; Haffner D; Johnson RJ; Mitsnefes MM; Schaefer F; Jaure A; Furth SL
Am J Kidney Dis; 2023 Apr; 81(4):466-474. PubMed ID: 36410592
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
